7 results about "Sevelamer" patented technology

The invention relates to a sevelamer carbonate tablet and a preparation method thereof. The preparation method comprises the following steps: carrying out wet granulation on calcium carbonate, microcrystalline cellulose (internally added) and purified water, and carrying out dry granulation on the prepared particles, sevelamer carbonate, microcrystalline cellulose (externally added) and magnesium stearate. The prepared tablet has good moisture uniformity and low hygroscopicity, the storage stability is improved, meanwhile, standing balance is not needed, the preparation time is greatly shortened, the production efficiency is improved, and a new thought is provided for mass production.

The invention provides sevelamer carbonate oral gel as well as a preparation method and application thereof, and belongs to the technical field of veterinary drug preparation. The sevelamer carbonate oral gel is prepared from 3% of sevelamer carbonate, 0.5%-1.0% of gel, 1%-3% of phagostimulant, 0-1.5% of potassium gluconate, 5% of glycerinum and the balance purified water. The sevelamer carbonate oral gel can effectively control hyperphosphatemia of cats suffering from chronic kidney diseases and prevent hypokalemia to a certain extent. The oral gel is convenient to use and only needs to be mixed for administration every day, and the oral gel is added with a cat phagostimulant, so that the mouth feel and the fragrance are improved to better conform to the taste of cats, and the cats can conveniently take medicine by themselves. Compared with tablets, the sevelamer carbonate oral gel has a better serum phosphorus concentration control effect and is more suitable for sick cats to use for a long time.

Compositions and principles for use before parturition in the prophylactic treatment of hypocalcemia in ruminant animals include compositions having phosphate binders for the prophylactic treatment of parturient hypocalcemia in ruminant animals. These compositions are presented in unit dosage forms, with one or more doses administered daily to the gastrointestinal tract of the ruminant animal, or in wet form. The composition contains one or more phosphate binders and one or more nutrients selected from minerals, vitamins, and amino acids, as well as a composition that includes an inhibitor of the small intestinal Na-phosphate transporter for the prophylactic treatment of parturient hypocalcemia in ruminant animals. Phosphate binders are selected from aluminum, iron, sevelamer, and lanthanum salts, with either inorganic or organic acids, hydrates thereof, or any mixture thereof.

The present invention relates to an oral formulation comprising sevelamer or a pharmaceutically acceptable salt thereof, and a method for preparing the same. Since the formulation is prepared through fluidized bed granulation, damage to the formulation is reduced and variation caused by abrasion is decreased, such that superior quality can be maintained. In particular, the formulation of the present invention has a smaller granule size while exhibiting increased uniformity, thereby improving medication convenience through reduction in the size of the formulation.

The present application relates to the technical field of preparation of sevelamer carbonate tablets, in particular to a sevelamer carbonate coated tablet and a preparation method thereof. The preparation method of the sevelamer carbonate coated tablet comprises: homogenizing sevelamer carbonate raw materials, a filler and a solvent, then performing spray drying, and then mixing the disintegrating agent and the lubricant uniformly, and then performing tabletting. The hardness of the tablet prepared by the preparation method is above 500N, the surface of the tablet is smooth, the tablet can be normally coated without using a special coating process, and the coated tablet prepared meets the requirements of disintegration time and stability.

The present application relates to the technical field of pharmaceutical preparations, in particular to a powder aerosol intermediate composition and a preparation method thereof, a sodium ciprofloxacin inhalation powder aerosol and an application thereof. The raw and auxiliary materials of the intermediate composition include 1-7 wt% of sodium ciprofloxacin, 92-98 wt% of lactose and not more than 1% of magnesium stearate, in terms of mass percentage fraction; the D 50 of the sodium ciprofloxacin is 1-5 microns; the D 50 of the lactose is 100-150 microns. The intermediate composition can be used for preparing the sodium ciprofloxacin inhalation powder aerosol, and can realize efficient delivery of the sodium ciprofloxacin, improve the delivery efficiency of the sodium ciprofloxacin at a target site, and reduce systemic side effects. The sodium ciprofloxacin inhalation powder aerosol can be used for treating mild diseases such as cystic fibrosis, interstitial pneumonia and idiopathic pulmonary fibrosis, and thus expands the indications of the sodium ciprofloxacin.